Muna Therapeutics–Golgi Neurosciences: investment, 202307 existent investment at time of spin-off of Golgi Neurosciences from Axxam

	Period	2023-07-05
	Money taker	Muna Therapeutics ApS
	Money source	Golgi Neurosciences S.r.l.
	Product	small-molecule drug
	Product 2	drug discovery

Golgi Neurosciences S.r.l.. (7/5/23). "Press Release: Golgi Neurosciences, a Unique Incubator to Combat Neurodegenerative Disorders, Starts Operating". Milan.

Golgi Neurosciences Srl is proud to announce its launch as an independent and unique incubator, dedicated to the discovery and development of innovative small molecule treatments to combat neurodegenerative diseases.

Golgi Neurosciences was incorporated in Milano (Italy) as an independent company after the carve-out of Axxam’s proprietary Discovery Research Unit, responsible for developing internal drug candidates, through a demerger process.

Golgi Neurosciences already holds an impressive portfolio of six participated biotech companies, including Acousia Therapeutics GmbH, Rewind Therapeutics NV, Libra Therapeutics Inc., Muna Therapeutics ApS, Lario Therapeutics Ltd and the recently added Breye Therapeutics ApS, along with a rich pipeline of innovative discovery programs, available for partnering or further company creation.

Golgi Neurosciences strongly benefits from the experience maturated over many years conducting
successful small molecule-based discovery programs on CNS targets and has an established network of leading drug discovery experts in the field as well as long standing collaborations with renowned international research centers.

“We are fully committed to make an impact for the benefit of patients suffering from dreadful diseases with high unmet medical need, such as Alzheimer’s Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis” said Chiara Liberati, Managing Director of Golgi Neurosciences.

“The world's population is getting older. There were about 1 billion people 60 years old or over in 2017: this number is projected to reach nearly 2.1 billion by 2050. Consequently, neurodevelopmental disorders are increasing in frequency, and a much deeper knowledge of the brain is mandatory to empower the discovery of the next wave of groundbreaking drugs”.

“We were inspired by the Golgi apparatus inside a cell as a way of describing the modus operandi of Golgi Neurosciences: here ideas are coming in like vesicles of the cis-Golgi, matured inside and released by the trans-Golgi as NewCos or collaboration deals. Apart from the link to the Golgi apparatus, Golgi Neurosciences has been named as a tribute to Camillo Golgi (1843 – 1926), an outstanding Italian biologist and pathologist known for his pioneering work on the central nervous system, for which he won the Nobel Prize in Physiology and Medicine in 1906, the first in Neurosciences and the first to an Italian scientist. Worth to mention, Camillo Golgi was born in Corteno, near Milan, where Golgi Neurosciences is based.”

Stefan Lohmer, Chairman of the Board of Golgi Neurosciences added: “Golgi Neurosciences’ mission is to pave the way to the generation of new small molecule drugs to cure devastating neurodegenerative diseases. Golgi Neurosciences is a unique incubator which starts already at day 1 with a very strong portfolio of companies and a significant number of assets, thus setting the stage for the creation of further companies or for partnering. An excellent network with world leading experts for neurodegenerative diseases has been already established and will be further expanded in the upcoming years. Based on our philosophy at Golgi, fundamental and reproducible science is absolutely mandatory in order to generate breakthrough treatment opportunities. Therefore «Let Science» always talk first! “

About Golgi Neurosciences Srl

Golgi Neurosciences is a biotech incubator fully dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases with high unmet need. The incubator already boasts a broad portfolio of clinical and preclinical stage participated companies, focused on programs for devastating diseases such as Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Retinopathies. Moreover, Golgi Neurosciences is progressing a rich pipeline of proprietary projects on innovative targets, available for partnering. The Company is based in Milan (Italy). For more information, please visit www.golgineurosciences.com.

Record changed: 2023-08-08

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)